1 citations
,
January 2017 in “Journal of Clinical Trials & Patenting” The lotion safely and effectively reduces unwanted hair growth.
2 citations
,
April 2022 in “Cutaneous and Ocular Toxicology” Tofacitinib may help treat hair loss in children with alopecia areata.
January 2026 in “Andrology” PRP injections are safe but don't significantly improve Peyronie's Disease.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
March 2025 in “Pediatric Rheumatology” Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
March 2026 in “Clinical and Experimental Medicine” Extracellular vesicles are important for disease treatment and monitoring.
June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
10 citations
,
October 2014 in “Plastic & Reconstructive Surgery Global Open” Botulinum toxin type A injections improved hair growth and scalp health in a woman with radiation-induced hair loss.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
5-ARI therapy may help prevent prostate cancer progression.
4 citations
,
December 2014 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” The excimer lamp is a safe and effective treatment for severe alopecia areata.
84 citations
,
February 2015 in “Experimental Dermatology” PPARγ is crucial for skin health but can have both beneficial and harmful effects.
15 citations
,
April 2011 in “Pediatric Nephrology” New treatments for lupus show promise, but more research is needed, especially for children.
October 2025 in “International Journal of Dermatology” JAK inhibitors may help treat certain types of hair loss, but more research is needed.
34 citations
,
January 1995 in “The Journal of Clinical Endocrinology and Metabolism” 505 citations
,
October 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
4 citations
,
February 2018 in “World journal of surgical oncology” A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
69 citations
,
February 2008 in “The American journal of pathology” Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
April 2025 in “Cermin Dunia Kedokteran” Graves' disease is a common cause of hyperthyroidism, mainly in women, treated with medication, iodine, or surgery, with varying outcomes.
2 citations
,
October 2025 in “Frontiers in Medicine” Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
1 citations
,
June 2001 in “Annals of Internal Medicine” The conclusion is that maintaining blinding in clinical trials is crucial for reliable results.
March 2007 in “Journal of Cell Science” K10 may not prevent tumors as previously thought and might increase benign tumor risk.
8 citations
,
August 1987 in “The Journal of Dermatology” BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
October 2014 in “Cancer research” Blocking mTORC1 reduces skin tumor growth in mice.